Form 4: Forte Biosciences CEO Exercises RSUs, Sells Shares for Tax
Insider Transaction Report
Paul A. Wagner, CEO of Forte Biosciences, exercised restricted stock units and sold a portion of the resulting shares for tax obligations.
Summary
- Paul A. Wagner, who serves as CEO, Secretary, and Chair of the Board for Forte Biosciences, Inc. (FBRX), reported changes in his beneficial ownership.
- On October 1, 2025, Wagner acquired 1,250 shares of common stock through the exercise of restricted stock units (RSUs) at a price of $0 per share.
- Concurrently, Wagner disposed of 98 shares of common stock at a price of $14.52 per share, a transaction typically conducted to cover tax withholding obligations associated with RSU vesting.
- Following these transactions, Wagner directly beneficially owns 82,092 shares of common stock and 6,250 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral, routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. It does not indicate significant positive or negative sentiment about the company's prospects or operations.
Positives
- The exercise of restricted stock units indicates the continued vesting of executive compensation, aligning management's interests with long-term company performance.
Negatives
- A small number of shares were sold, which slightly reduces the reporting person's direct equity stake, though this was for tax withholding purposes.
Future Outlook
The filing, a Form 4, is transactional in nature and does not provide specific forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing is specific to an individual's insider trading activity and does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine insider compensation event. No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.
Next Steps
- Future vesting of the remaining 6,250 restricted stock units will occur on Quarterly Vesting Dates (January 1, April 1, July 1, and October 1), subject to the reporting person's continued service as a Service Provider.
Key Dates
| Date | Description |
|---|---|
| 2023-02-01 | Reference date for RSU vesting schedule commencement, with one-sixteenth of RSUs vesting on each Quarterly Vesting Date thereafter. |
| 2025-10-01 | Date of RSU exercise and subsequent disposition of shares for tax withholding. |
| 2025-10-02 | Signature date of the reporting person on the Form 4 filing. |
Recommendation
holdThe filing details a routine insider transaction where the CEO exercised restricted stock units and sold a small portion to cover tax liabilities. This is a common compensation event and does not provide new fundamental information about the company's performance or future prospects that would warrant a change in an investment recommendation.
Keywords
Forte Biosciences, FBRX, Paul A. Wagner, Form 4, Insider Transaction, RSU, Restricted Stock Units, Stock Option Exercise, Share Sale, CEO, Director, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.